New York State (NYS) Medicaid Policy and Billing Guidance for Pharmacy Reimbursement of COVID-19 Oral Antivirals

Effective December 29, 2021, NYS Medicaid will reimburse pharmacies for dispensing COVID-19 oral antivirals with no member cost-sharing. This policy applies to both Medicaid fee for service (FFS) and Medicaid Managed Care (MMC) to include Mainstream MMC plans, HIV Special Needs Plans (HIV SNPs), and Health and Recovery Plans (HARPs).

Coverage Policy

- COVID-19 oral antivirals must be approved or granted Emergency Use Authorization (EUA) through the FDA and must be ordered in accordance with the FDA approval or authorization.
- COVID-19 oral antivirals, Paxlovid and molnupiravir, must be prescribed for an individual patient by a physician, nurse practitioner, or physician assistant licensed or authorized under New York State law to prescribe oral antivirals.
- Prior authorization is not required.
- Providers are prohibited from charging Medicaid members a co-payment or any cost-sharing responsibility for COVID-19 oral antivirals, consistent with other COVID-19 Medicaid guidance.

FFS Pharmacy Billing

- To bill for the dispensing of COVID-19 oral antivirals, the pharmacy must submit a valid National Drug Code (NDC). NDCs are listed in the Emergency Use Authorization for each COVID-19 oral antiviral. Additionally, providers can also perform a search for each NDC using the eMedNY formulary search page.
- Pharmacies must bill with a cost of $10.09 and will be reimbursed a $10.08 dispensing fee.

Billing Instructions

<table>
<thead>
<tr>
<th>NCPDP D.0. Claim Segment Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>436-E1 (Product/Service ID Qualifier)</td>
<td>Enter a value of &quot;03&quot; (NDC)</td>
</tr>
<tr>
<td>411-DB (Prescriber ID)</td>
<td>Enter Prescriber National Provider Identifier (NPI) number</td>
</tr>
<tr>
<td>461-EU (Prior Authorization Type Code)</td>
<td>Enter 04= Exempt Copay*</td>
</tr>
</tbody>
</table>

*Claims submitted for COVID-19 related testing, evaluation, and treatment that do not adjudicate with a zero copayment can be systematically adjusted by utilizing the National Council for Prescription Drug Programs (NCPDP) field. This instruction can be
found in the *NCPDP D.0 Companion Guide*, located on the [eMedNY "5010/D.0 Transaction Instructions" web page](http://www.emedny.org).

**MMC Pharmacy Billing**

The COVID-19 oral antivirals’ billing guidance and reimbursement amounts are specific to Medicaid FFS. Individual MMC plans should be contacted for their specific reimbursement and billing guidance. Plan information can be found by visiting the following website: [Medicaid Managed Care Pharmacy Benefit Information Center](http://www.medicaid.ny.gov).

**Information on Ordering and Availability**

- Additional information on the Public Health Emergency and COVID-19 Therapeutics, including antivirals and monoclonal antibodies, can be found here: [COVID-19 Therapeutics](http://www.ny.gov).

**Questions**

- For Medicaid FFS billing questions, please contact the eMedNY Call Center at (800) 343-9000.
- For Medicaid FFS Pharmacy Policy questions, please contact: [ppno@health.ny.gov](mailto:ppno@health.ny.gov).